Clinical Trial Update: First-in-Human Study of ALN-SNCA in Adult Participants With Early Parkinson's Disease (PD) [Phase 1]

View source ↗

Summary

Regeneron is conducting a first-in-human Phase 1 study of ALN-SNCA in adults with early Parkinson's disease, and the trial is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• ALN-SNCA

Snippet

Sponsor: Regeneron Pharmaceuticals | Conditions: Parkinsons Disease | Phase 1 | Status: RECRUITING